Clinical Trial Update: A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A multi-center Phase 1/2 trial is evaluating androgen suppression with abiraterone acetate and leuprolide plus a PARP inhibitor and stereotactic body radiothera…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Abiraterone acetate (Abiraterone acetate)
• Leuprolide (Leuprolide acetate)
• PARP inhibitor

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING